Victory Capital Management Inc. Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Victory Capital Management Inc. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 0.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 839,602 shares of the specialty pharmaceutical company’s stock after selling 7,641 shares during the period. Victory Capital Management Inc. owned 1.57% of Supernus Pharmaceuticals worth $26,919,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in SUPN. Stephens Investment Management Group LLC lifted its holdings in Supernus Pharmaceuticals by 27.2% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company’s stock worth $46,014,000 after purchasing an additional 337,902 shares in the last quarter. Lisanti Capital Growth LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $8,878,000. GW&K Investment Management LLC lifted its holdings in Supernus Pharmaceuticals by 13.0% in the 4th quarter. GW&K Investment Management LLC now owns 1,836,466 shares of the specialty pharmaceutical company’s stock worth $53,551,000 after purchasing an additional 210,976 shares in the last quarter. Congress Wealth Management LLC DE purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $3,319,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $2,023,000.

Analyst Ratings Changes

SUPN has been the topic of several recent research reports. StockNews.com raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 18th. TheStreet cut Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, April 18th.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $32.02 on Thursday. The stock’s fifty day moving average is $29.00 and its 200 day moving average is $29.77. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $34.50. The firm has a market capitalization of $1.71 billion, a PE ratio of 24.63 and a beta of 1.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.69 and a current ratio of 2.00.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last released its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.17. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. The company had revenue of $152.50 million for the quarter, compared to analyst estimates of $150.47 million. During the same quarter in the prior year, the firm posted $0.11 EPS. Supernus Pharmaceuticals’s quarterly revenue was up 16.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.64 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Want More Great Investing Ideas?

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.